SCHEMBL274647

SCHEMBL274647

C=C(N=Cc1cc(F)ccc1Oc1ccc(OC)cc1)O[Si](C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.38
NFE2L2 Q16236 2/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
PLA2G2A P14555 1/20 0.35
TSPO P30536 3/20 0.35
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279191 1.00 LMNA (0.43) LMNAHTTHPGDALDH1A1L3MBTL1
SCHEMBL275677 0.94 LMNA (0.44) LMNAHTTHPGDALDH1A1L3MBTL1
SCHEMBL279179 0.94 LMNA (0.44) LMNAHTTHPGDALDH1A1L3MBTL1
SCHEMBL8043283 0.88 ERN1 (0.38) LMNAHTTALDH1A1L3MBTL1GAA
SCHEMBL275612 0.87 TBXA2R (0.38) LMNAALDH1A1L3MBTL1SCN8ASCN10A
SCHEMBL278967 0.87 TBXA2R (0.38) LMNAALDH1A1L3MBTL1SCN8ASCN10A
SCHEMBL278919 0.86 LMNA (0.40) LMNAHTTHPGDALDH1A1GAA
SCHEMBL279190 0.86 CCR5 (0.43) LMNAHTTHPGDALDH1A1L3MBTL1
SCHEMBL279339 0.85 LMNA (0.40) LMNAHPGDALDH1A1L3MBTL1CYP1A2
SCHEMBL275415 0.84 MAPT (0.38) HPGDL3MBTL1CYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT LMNA 549/4885HTT 2366/4885HPGD 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.